Brivanib治疗肝癌的临床研究进展
As an inhibitor of fibroblast growth factor receptor (FGFR)-1, FGFR-2, FGFR-3, vascular endothelial growth factor receptor (VEGFR)-2, and VEGFR-3, brivanib can inhibit tumor angiogenesis and growth. Phase Ⅰ and Ⅱ clinical trials have demonstrated the safety and efficacy of brivanib in the treatment...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Department of Journal of Clinical Hepatology
2014-04-01
|
| Series: | Linchuang Gandanbing Zazhi |
| Subjects: | |
| Online Access: | http://www.lcgdbzz.org/qk_content.asp?id=5736&ClassID=331688 |